CA3052247A1 - N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or iraki inhibitors fortreating cancer - Google Patents
N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or iraki inhibitors fortreating cancer Download PDFInfo
- Publication number
- CA3052247A1 CA3052247A1 CA3052247A CA3052247A CA3052247A1 CA 3052247 A1 CA3052247 A1 CA 3052247A1 CA 3052247 A CA3052247 A CA 3052247A CA 3052247 A CA3052247 A CA 3052247A CA 3052247 A1 CA3052247 A1 CA 3052247A1
- Authority
- CA
- Canada
- Prior art keywords
- branched
- straight
- alkyl
- halide
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762453192P | 2017-02-01 | 2017-02-01 | |
| US62/453,192 | 2017-02-01 | ||
| PCT/IL2018/050100 WO2018142393A1 (en) | 2017-02-01 | 2018-01-30 | N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or iraki inhibitors for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3052247A1 true CA3052247A1 (en) | 2018-08-09 |
Family
ID=61198874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3052247A Pending CA3052247A1 (en) | 2017-02-01 | 2018-01-30 | N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or iraki inhibitors fortreating cancer |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11072599B2 (instruction) |
| EP (1) | EP3577108B1 (instruction) |
| JP (1) | JP7142646B2 (instruction) |
| KR (1) | KR20190115017A (instruction) |
| CN (1) | CN110475771B (instruction) |
| AU (1) | AU2018215809B2 (instruction) |
| CA (1) | CA3052247A1 (instruction) |
| ES (1) | ES2902885T3 (instruction) |
| IL (1) | IL268128B2 (instruction) |
| MX (1) | MX394556B (instruction) |
| NZ (1) | NZ755447A (instruction) |
| RU (1) | RU2761457C2 (instruction) |
| SG (1) | SG11201906681PA (instruction) |
| TW (1) | TW201837027A (instruction) |
| WO (1) | WO2018142393A1 (instruction) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3331877T (pt) * | 2015-08-04 | 2021-12-27 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Derivado de pirimidina pirazol e usos do mesmo |
| EP3749666A1 (en) * | 2018-02-08 | 2020-12-16 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use |
| WO2021000957A1 (zh) * | 2019-07-04 | 2021-01-07 | 北京国鸿生物医药科技有限公司 | 一种杂环化合物、其药物组合物及用途 |
| JP2023541463A (ja) * | 2020-09-17 | 2023-10-02 | ヤンセン ファーマシューティカ エヌ．ベー． | カゼインキナーゼ１デルタモジュレーター |
| CA3215697A1 (en) * | 2021-04-28 | 2022-11-03 | Cornell University | Soluble adenylyl cyclase (sac) inhibitors and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007129195A2 (en) | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
| CN105367577B (zh) * | 2010-07-13 | 2019-04-23 | 弗·哈夫曼-拉罗切有限公司 | 作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物 |
| EP2835131B1 (en) | 2010-12-14 | 2017-09-06 | Electrophoretics Limited | Casein kinase 1delta (CK1delta) inhibitors |
| MX347191B (es) | 2011-11-04 | 2017-04-19 | Jasco Pharmaceuticals Llc | Inhibidores de aminopirimidina cinasa. |
| EP3049086A4 (en) | 2013-09-27 | 2017-02-22 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| WO2015058140A1 (en) | 2013-10-18 | 2015-04-23 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
| KR20170086057A (ko) * | 2014-11-20 | 2017-07-25 | 메르크 파텐트 게엠베하 | Irak 억제제로서 헤테로아릴 화합물 및 이들의 용도 |
| CN113350352B (zh) | 2015-03-23 | 2024-09-10 | 天莅生物科技私人有限公司 | 呼吸性疾病的治疗 |
| PT3331877T (pt) | 2015-08-04 | 2021-12-27 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Derivado de pirimidina pirazol e usos do mesmo |
-
2018
- 2018-01-30 RU RU2019127038A patent/RU2761457C2/ru active
- 2018-01-30 CA CA3052247A patent/CA3052247A1/en active Pending
- 2018-01-30 JP JP2019561389A patent/JP7142646B2/ja active Active
- 2018-01-30 KR KR1020197025024A patent/KR20190115017A/ko not_active Ceased
- 2018-01-30 MX MX2019009083A patent/MX394556B/es unknown
- 2018-01-30 NZ NZ755447A patent/NZ755447A/en unknown
- 2018-01-30 ES ES18705024T patent/ES2902885T3/es active Active
- 2018-01-30 US US16/482,199 patent/US11072599B2/en active Active
- 2018-01-30 IL IL268128A patent/IL268128B2/en unknown
- 2018-01-30 WO PCT/IL2018/050100 patent/WO2018142393A1/en unknown
- 2018-01-30 SG SG11201906681PA patent/SG11201906681PA/en unknown
- 2018-01-30 EP EP18705024.0A patent/EP3577108B1/en active Active
- 2018-01-30 AU AU2018215809A patent/AU2018215809B2/en not_active Ceased
- 2018-01-30 TW TW107103255A patent/TW201837027A/zh unknown
- 2018-01-30 CN CN201880022829.8A patent/CN110475771B/zh not_active Expired - Fee Related
-
2021
- 2021-07-26 US US17/384,922 patent/US11999721B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019127038A (ru) | 2021-03-02 |
| CN110475771A (zh) | 2019-11-19 |
| US20200354340A1 (en) | 2020-11-12 |
| KR20190115017A (ko) | 2019-10-10 |
| IL268128B2 (en) | 2023-03-01 |
| MX394556B (es) | 2025-03-24 |
| AU2018215809A1 (en) | 2019-08-15 |
| EP3577108A1 (en) | 2019-12-11 |
| NZ755447A (en) | 2023-05-26 |
| ES2902885T8 (es) | 2022-04-06 |
| JP7142646B2 (ja) | 2022-09-27 |
| SG11201906681PA (en) | 2019-08-27 |
| EP3577108B1 (en) | 2021-10-20 |
| IL268128A (en) | 2019-09-26 |
| RU2761457C2 (ru) | 2021-12-08 |
| US20220017493A1 (en) | 2022-01-20 |
| TW201837027A (zh) | 2018-10-16 |
| IL268128B (en) | 2022-11-01 |
| AU2018215809B2 (en) | 2021-12-23 |
| JP2020505468A (ja) | 2020-02-20 |
| RU2019127038A3 (instruction) | 2021-03-17 |
| US11999721B2 (en) | 2024-06-04 |
| MX2019009083A (es) | 2019-09-10 |
| CN110475771B (zh) | 2022-09-02 |
| US11072599B2 (en) | 2021-07-27 |
| WO2018142393A1 (en) | 2018-08-09 |
| ES2902885T3 (es) | 2022-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11925641B2 (en) | Pyrazole pyrimidine derivative and uses thereof | |
| US11999721B2 (en) | Pyrazole compounds and uses thereof | |
| ES2620316T3 (es) | Cicloalquenopirazoles sustituidos como inhibidores de BUB1 para el tratamiento del cáncer | |
| US9567342B2 (en) | Certain protein kinase inhibitors | |
| US9085599B2 (en) | 2′allene-substituted nucleoside derivatives | |
| CA3214900A1 (en) | Carboxamide pyrolopyrazine and pyridine compounds useful as inhibitors of myt1 and use thereof in the treatment of cancer | |
| ES2906785T3 (es) | Pirazoles 3,5-disustituidos útiles como inhibidores de la quinasa de punto de control 1 (CHK1), y sus preparaciones y aplicaciones | |
| KR102429355B1 (ko) | 티에노피리미딘 화합물, 그의 제조 방법, 약학 조성물 및 용도 | |
| CN101679429A (zh) | 5-氨基吡唑-3-基-3h-咪唑并[4,5-b]吡啶衍生物及其治疗癌的用途 | |
| HK40019133B (en) | N1-(4-(5-(cyclopropylmethyl)-1-methyl-1h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or iraki inhibitors for treating cancer | |
| HK1256535B (en) | Pyrazole pyrimidine derivative and uses thereof | |
| NZ739511B2 (en) | Pyrazole pyrimidine derivative and uses thereof | |
| HK1141800A (en) | 5-aminopyrazol-3-yl-3h-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20211231 |
|
| EEER | Examination request |
Effective date: 20211231 |
|
| EEER | Examination request |
Effective date: 20211231 |
|
| EEER | Examination request |
Effective date: 20211231 |
|
| EEER | Examination request |
Effective date: 20211231 |